Clinical-stage biopharmaceutical company MacroGenics has entered into a global collaboration and license agreement with US-based biotechnology company Janssen Biotech to develop MGD015, a preclinical bispecific molecule.
MGD015 uses MacroGenics’ dual-affinity re-targeting (DART) platform to simultaneously target CD3 and an undisclosed tumour target, for the possible treatment of a wide range of hematological malignancies and solid tumours.
Go deeper with GlobalData
MacroGenics has revealed that MGD015 is capable of killing these targeted CD3 both in vitro and in vivo.
Under the deal, as well as subject to the termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act, MacroGenics will receive an upfront license fee worth $75m.
Janssen, on the other hand, will have to complete IND-enabling activities, along with being responsible for further clinical development of MGD015.
MacroGenics also expects to receive up to an additional $665m in regulatory, clinical and commercialisation milestone payments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMacroGenics president and CEO Scott Koenig said: "MGD015 is a promising product candidate that employs MacroGenics’ proprietary DART platform to enable a potent redirected T-cell killing mechanism with ‘off-the-shelf’ convenience.
"This approach is already being evaluated in five other clinical-stage DART programmes.
"Janssen represents the ideal partner for MGD015, given its track record of successfully developing and commercialising transformative oncology therapies."
After its commercialisation, MacroGenics will be able to receive double-digit royalties on any global net sales, as well as promote MGD015 in the US in collaboration with Janssen.
